Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial

Affiliations

• ¹ Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada [email protected].
• ² Department of Anesthesia, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
• ³ Brigham and Women's Hospital Heart Vascular Center and Harvard Medical School, Boston, MA.
• ⁴ Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.
• ⁵ Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN.
• ⁶ Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
• ⁷ Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
• ⁸ CNR Institute of Clinical Physiology, Pisa, Italy.
• ⁹ Boehringer Ingelheim International GmbH, Ingelheim, Germany.
• ¹⁰ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.